Olink launched Proseek Multiplex—a new generation of multiplexed protein biomarker immunoassays based on its proprietary Proximity Extension Assay (PEA) platform. With this introduction, biomarker researchers can quantify 92 proteins in a one microliter sample without compromising data quality orperformance.

First in the range is Proseek Multiplex Oncology I ^96x96, a ready-to-use kit capable of analyzing 96 samples against a panel of analytes such as growth factors,inflammatory markers, soluble receptors, and cancer antigens. Further Proseek 92-plex panels for cardiovascular disease, inflammation, and diabetes will be introduced through 2013.

Minimal sample consumption makes Proseek Multiplex suitable for retroactively mining precious biobanked serum samples for novel multivariate biomarker signatures. It can also provide novel biomarker insights from sample types such as tissue lysates of needle biopsies and micro dialysis samples. Even in these small samples Proseek Multiplex can provide accurate quantification below pico-gram per milliliter levels.

Proseek is based on the proprietary PEA technology developed at Olink. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules which upon target binding give rise to new DNA amplicons each ID-barcoding their respective antigens. Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR.

Olink AB , +46-0-18-444-3970, www.olink.com